Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATHER Plus short-cycle HIV therapy in adolescents
PACTR202103692694276Phase 3Unknown
- Sponsor
- University College London
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of dolutegravir, tenofovir, lamivudine and emtricitabine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University College London. Primary endpoint: Confirmed virological rebound. Status: unknown.
02
Drugs
dolutegravirtenofovirlamivudineemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202103692694276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202103692694276.